Shares of Amarin Co. plc (NASDAQ:AMRN) have been given an average rating of “Buy” by the eight research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $34.00.

A number of research firms recently weighed in on AMRN. BidaskClub upgraded Amarin from a “hold” rating to a “buy” rating in a research note on Wednesday, February 27th. Cantor Fitzgerald restated a “buy” rating and issued a $35.00 price target on shares of Amarin in a research note on Friday, December 7th. Jefferies Financial Group set a $30.00 price target on Amarin and gave the company a “buy” rating in a research note on Thursday, December 20th. HC Wainwright restated a “buy” rating and issued a $51.00 price target on shares of Amarin in a research note on Thursday, January 17th. Finally, Citigroup dropped their price target on Amarin to $20.00 in a research note on Tuesday, January 8th.

AMRN opened at $20.33 on Friday. Amarin has a 1-year low of $2.35 and a 1-year high of $23.33. The company has a current ratio of 2.40, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $6.56 billion, a P/E ratio of -52.13 and a beta of 1.29.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). The company had revenue of $77.30 million during the quarter, compared to analyst estimates of $73.87 million. During the same quarter in the previous year, the business posted ($0.08) EPS. The company’s revenue for the quarter was up 43.4% compared to the same quarter last year. As a group, equities analysts expect that Amarin will post -0.17 earnings per share for the current year.

In other Amarin news, insider Steven B. Ketchum sold 17,041 shares of the stock in a transaction on Monday, December 31st. The stock was sold at an average price of $13.51, for a total transaction of $230,223.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Wayne Kalb sold 200,000 shares of the stock in a transaction on Wednesday, January 9th. The stock was sold at an average price of $15.26, for a total value of $3,052,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,841,072 shares of company stock worth $49,748,088 in the last quarter. Company insiders own 4.08% of the company’s stock.

A number of hedge funds have recently bought and sold shares of AMRN. Northern Trust Corp increased its position in Amarin by 20.9% during the 2nd quarter. Northern Trust Corp now owns 113,327 shares of the biopharmaceutical company’s stock worth $350,000 after buying an additional 19,590 shares during the period. Cambridge Investment Research Advisors Inc. grew its holdings in shares of Amarin by 165.5% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 31,125 shares of the biopharmaceutical company’s stock worth $506,000 after purchasing an additional 19,400 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Amarin by 113.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 76,916 shares of the biopharmaceutical company’s stock worth $1,251,000 after purchasing an additional 40,844 shares in the last quarter. MML Investors Services LLC grew its holdings in shares of Amarin by 66.4% during the 3rd quarter. MML Investors Services LLC now owns 23,336 shares of the biopharmaceutical company’s stock worth $380,000 after purchasing an additional 9,316 shares in the last quarter. Finally, Claraphi Advisory Network LLC grew its holdings in shares of Amarin by 5.8% during the 3rd quarter. Claraphi Advisory Network LLC now owns 55,521 shares of the biopharmaceutical company’s stock worth $903,000 after purchasing an additional 3,030 shares in the last quarter. Hedge funds and other institutional investors own 48.30% of the company’s stock.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Further Reading: Should I invest in “strong buy” stocks?

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.